Harnessing New Players in Atherosclerosis to Treat Heart Disease
Tuesday, September 24, 2013
Atherosclerosis is defined as a chronic inflammatory disease affecting arterial blood vessels involving dysregulation of the endothelial-leukocyte adhesive interactions, increased leukocyte apoptosis within the plaque, and defective phagocytosis of apoptotic cells. Despite the key role of monocytes/macrophages in atherosclerosis, mounting evidence suggests that dysregulation of other cell types may be independent risk factors for atherosclerosis. Leukocytes are produced daily and are derived from hematopoietic stem and progenitor cells within the bone marrow in a process call hematopoiesis. A better understanding of this process will open an avenue to identify new targets to fight atherosclerosis.
*Reception to follow.
|Nonmember (Student / Postdoc / Resident / Fellow)||$45|
The Biochemical Pharmacology Discussion Group is proudly supported by
Mission Partner support for the Frontiers of Science program provided by
* Presentation titles and times are subject to change.
September 24, 2013
Registration and continental breakfast
Welcome and Introduction
A transcriptional network underlies the identity and diversity of tissue macrophages
Monocyte behavior, imaging and targeting in atherosclerosis
Trapped in the plaque: Mechanisms of macrophage retention in atherosclerosis
Diabetes-accelerated atherosclerosis: Mechanistic insight based on mouse models
Antigen presentation in the atherosclerotic mouse aorta
Cholesterol efflux pathways suppress innate immune responses, auto-immunity and atherosclerosis
Regulation of pro-atherogenic T cell responses
T cell fate in atherosclerosis
Mercedes Beyna, MS
Pfizer Global Research and Development
Mercedes Beyna is a scientist in the Neuroscience Research Unit at Pfizer. Her research focuses on target identification and assay development in the areas of psychiatric as well as neurodegenerative disorders. Captivated by neuroscience, she has worked in the field for over 10 years, in both academic and industrial laboratory settings. Before joining pharmaceutical R&D, Mercedes held lab manager and senior lab technician positions at New York University (NYU). Mercedes attended Binghamton University, earning her undergraduate degree in Biology, and subsequently received her Master's Degree in Biology from NYU. As the Pfizer lead in the Biochemical Pharmacology Discussion Group at the New York Academy of Sciences, she enjoys developing interesting and educational symposia.
Laurent Yvan-Charvet, PhD
INSERM U1065/UNS, C3M
Dr. Laurent Yvan-Charvet obtained his PhD in Endocrinology in 2005 from the University of Paris XI, France. His postdoctoral research work in the laboratory of Alan Tall at Columbia University has been mainly focused on how regulation of inflammation and stem cell biology by cholesterol efflux pathways affect cardiovascular diseases. He was the recipient of the Roger Davis Award in 2010, a finalist of the I.H. Page Young Investigator Award in 2011 and the recipient of the EAS Young Investigator Award in 2013. After a contribution to the development of new therapeutics for cardiovascular diseases at Pfizer from 2012 to 2013, his current research interest as a group leader lies in hematopoietic cell metabolism—a new area of research for cardiovascular diseases.
Jennifer Henry, PhD
The New York Academy of Sciences
Karin Bornfeldt, PhD
University of Washington School of Medicine
Karin Bornfeldt received her PhD from Linköping University in Sweden in 1991. Later that year, she joined the University of Washington in Seattle to do a postdoctoral fellowship in the laboratory of Russell Ross, a leader in the field of cardiovascular research. She also worked closely with Edwin Krebs on signal transduction. She was appointed to the faculty in 1995, and is now Professor of Medicine and Pathology, and serves as Associate Director of the Diabetes and Obesity Center of Excellence and Deputy Director of the Diabetes Research Center at the University of Washington. She is a Fellow of the American Heart Association, a Consulting Editor for Arteriosclerosis, Thrombosis and Vascular Biology, and has served on the editorial boards of the Journal of Clinical Investigation, Circulation Research, Diabetes, and the Journal of Biological Chemistry. Her research is devoted to the mechanisms of cardiovascular complications of diabetes.
Elena V. Galkina, MD, PhD
Eastern Virginia Medical School
Elena Galkina received her BS in biology and chemistry from Saint-Petersburg State Technological Institute, Saint-Petersburg, Russia in 1995. She received her PhD in Immunology from the Institute for Experimental Medicine, Saint-Petersburg, Russia in 1999, where she performed her graduate research on the impact of acute phase proteins on neutrophil functions. From 2000 to 2003, she performed her postdoctoral research on the implication of L-selectin shedding in the regulation of T cell migration into lymph nodes at the National Institute for Medical Research, MRC, London, UK. In 2003, she moved to University of Virginia, Charlottesville, where she started to focus her research on the implication of the immune response in atherosclerosis as a postdoctoral fellow and later as a Research Assistant Professor. Dr. Galkina joined Eastern Virginia Medical School in 2008 and is currently Associate Professor in the Department of Microbiology and Molecular Cell Biology. Dr.Galkina's research focuses on the mechanisms of differentiation of T cell subsets in atherosclerosis and the role of T helper cells in atherogenesis. Dr. Galkina currently serves on the NHLBI VCMB study section and the American Heart Association ATVB Council Women's Leadership Committee. Dr.Galkina is also a Fellow of the American Heart Association.
Emmanuel L. Gautier, PhD
Washington University School of Medicine, St. Louis
Emmanuel Gautier obtained his PhD from Pierre and Marie Curie University in Paris in 2008. His graduate work was focused on the role of macrophage apoptosis, autoimmunity and dendritic cells in the pathogenesis of atherosclerosis. During his post-doctoral training in Gwendalyn Randolph lab he delineated the transcriptional network underlying the identity and diversity of tissue resident macrophages as well as the fate of inflammatory macrophages during inflammation. Dr Gautier is now starting his own group in the INSERM Unit 939 at the Pitié-Salpétrière Hospital in Paris.
Klaus Ley, MD
La Jolla Institute for Allergy and Immunology
Dr. Klaus Ley received his MD in medicine from Julius-Maximilians- Universität, Würzburg, Germany. He has two post-doctoral degrees in physiology from Freie Universität Berlin, Germany and biomedical engineering from UCSD, San Diego, CA.
Dr. Ley's research interest is focused on myeloid cells, specifically neutrophil and monocyte recruitment. Since 1980, he had published more than 200 original papers in peer-reviewed journals including Nature and Science. In 1991, Dr. Ley discovered that L-selectin was involved in leukocyte rolling in vivo. In 2007, his lab discovered a fundamental new signaling mechanism in neutrophils that appears to be very important in neutrophil recruitment. For his work on neutrophils and monocytes, Dr. Ley received the 2008 Bonazinga Award, the highest award of the Society for Leukocyte Biology, and the 2010 Malpighi Award, the highest award of the European Society for Microcirculation and Vascular Biology.
Dr. Ley's research in atherosclerosis started in 1997, when his lab discovered that P-selectin mediated rolling not only in venules, but also in inflamed arteries. His work is focused on the role of monocyte-derived cells in atherosclerosis. In 2001, his lab discovered CCL5 and CXCL1 as monocyte arrest chemokines relevant to atherosclerosis (Apoe−/− mouse model). Next, the lab investigated the role of platelets in promoting monocyte interactions with the vessel wall, which resulted in a publication in Nature Medicine in 2003. In 2006, the lab developed and published a method to measure the leukocyte content of the aortic wall by flow cytometry, a method that is now used by many labs around the world.
Andrew H. Lichtman, MD, PhD
Brigham and Women's Hospital, Harvard Medical School
Andrew Lichtman received and MD. and PhD degrees from the University of Rochester School of Medicine in 1981, trained in Anatomic Pathology at the Brigham and Women's Hospital (BWH) 1982–1985, and is currently Professor of Pathology at The BWH and Harvard Medical School (HMS). Dr. Lichtman's laboratory studies T cell-mediated immunity and immunopathology, with a focus on T cell-endothelial interactions, and the contribution of T cell responses to cardiovascular disease, including atherosclerosis and myocarditis. He has made important contributions to our current understanding of atherosclerosis as a chronic inflammatory disease of the arterial wall, sustained by innate and adaptive immune responses. Currently is research is focused on cellular and molecular mechanism of regulation inflammation in arteries and in the myocardium, including the role of T cell costimulatory and inhibitory pathways. Dr. Lichtman is also active in education through course directing and curriculum reform at Harvard Medical School, coauthoring two textbooks of immunology and serving as both Education and Publication Chair of the Federation of Clinical Immunology Societies (FOCIS). He has received many teaching and mentoring awards at HMS, and is the 2014 recipient of the American Society of Investigative Pathology Distinguished Educator Award.
Kathryn J. Moore, PhD
New York University Medical Center
Kathryn Moore is Professor at New York University School of Medicine in the Departments of Medicine and Cell Biology. Dr. Moore has made seminal contributions to our understanding of the pathways that promote atherosclerosis, in such varied areas as innate immunity, immune cell trafficking, and microRNA regulation of cholesterol metabolism. In recognition of these contributions, she has been the recipient of several prestigious awards, including the Ellison Foundation New Scholar in Aging Award, the American Heart Association's Special Recognition Award in Vascular Biology and the Jeffrey M. Hoeg Arteriosclerosis Award for Basic Science and Clinical Research.
Matthias Nahrendorf, MD, PhD
Harvard Medical School
Dr. Nahrendorf is currently an associate professor at Harvard Medical School and director of the Mouse Imaging Program at the Center for Systems Biology at MGH. He completed his joint PhD and MD studies at the University of Heidelberg in Germany before moving to the University of Wurzberg where he did his residency, fellowship and postdoctoral training. Dr. Nahrendorf joined Harvard Medical School in 2004. His laboratory focuses on the cellular and molecular processes in atherosclerosis and after myocardial infarction, using the entire spectrum of imaging modalities, including MRI, nuclear, and optical imaging techniques, with a special interest in multimodal imaging. These technologies are embedded in a biologically driven research program that aims at a systematic understanding of inflammation at a basic level while keeping a rigorous translational perspective.
Alan R. Tall, MD, PhD
Columbia University Medical Center
Dr. Tall is internationally recognized for his work in plasma lipoprotein metabolism and atherosclerosis, especially in relation to plasma high density lipoproteins (HDL). Dr. Tall and collaborators discovered mutations in the cholesteryl ester transfer protein (CETP) gene that are associated with dramatically increased HDL and reduced LDL levels, establishing the role of CETP in the regulation of lipoproteins and identifying CETP as a potential therapeutic target. Dr. Tall and colleagues have done research on the ATP binding cassette transporters ABCA1 and ABCG1 that promote cholesterol efflux from macrophage foam cells to apoA-1 and HDL particles, respectively. Recently, Dr. Tall and colleagues have identified a key role of cholesterol efflux pathways in limiting the proliferation of hematopoietic stem and progenitor cells and thus the pro-atherogenic production of inflammatory cells and platelets. Dr Tall is an Associate Editor of Circulation Research and serves on the editorial boards of the Journal of Clinical Investigation and the ATVB Journal.
A Transcriptional Network Underlies the Identity and Diversity of Tissue Macrophages
Emmanuel L. Gautier, Washington University School of Medicine, St. Louis
Monocyte Behavior, Imaging and Targeting in Atherosclerosis
Matthias Nahrendorf, MD, PhD, Harvard Medical School
Trapped in the Plaque: Mechanisms of Macrophage Retention in Atherosclerosis
Kathryn J. Moore, PhD, New York University Medical Center
Diabetes-accelerated Atherosclerosis: Mechanistic Insight Based on Mouse Models
Karin Bornfeldt, PhD, University of Washington School of Medicine
Antigen Presentation in the Atherosclerotic Mouse Aorta
Klaus Ley, MD, La Jolla Institute for Allergy and Immunology
Regulation of Pro-atherogenic T Cell Responses
Andrew H. Lichtman, MD, PhD, Brigham and Women's Hospital, Boston, MA
Cholesterol Efflux Pathways Suppress Innate Immune Responses, Auto-immunity and Atherosclerosis
Alan Tall, Columbia University, New York
T Cell Fate in Atherosclerosis
Elena Galkina, PhD, Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School
Supported by NHLBI RO1 HL107522 (E.G.) and AHA Pre-doctoral Fellowship 11PRE7520041 (M.B.).
Travel & Lodging
The New York Academy of Sciences
7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
Hotels Near 7 World Trade Center
Recommended partner hotel
Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.
Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.
Other nearby hotels